ExploRNA Therapeutics, Łukasiewicz - IChP partner on mRNA cap analog manufacturing
ExploRNA Therapeutics and Łukasiewicz - IChP have formed a strategic partnership to advance Good Manufacturing Practice (GMP) production of next-generation mRNA cap analogs. The collaboration aims to accelerate the development of novel therapeutics.
Biotechnology company ExploRNA Therapeutics and the Łukasiewicz Research Network – Industrial Chemistry Institute (Łukasiewicz - IChP) have entered into a strategic partnership aimed at advancing the Good Manufacturing Practice (GMP) production of next-generation mRNA cap analogs.
The collaboration seeks to scale up the manufacturing process for these crucial mRNA components, which are essential for the development of novel therapeutics. ExploRNA Therapeutics specializes in mRNA capping technologies, while Łukasiewicz - IChP brings expertise in industrial chemistry and manufacturing.
This partnership is expected to accelerate the translation of research findings into clinical applications. By ensuring a reliable and scalable GMP-compliant supply of mRNA cap analogs, the companies aim to facilitate the development of new mRNA-based drugs and vaccines.
The agreement highlights the growing importance of specialized manufacturing capabilities in the biotechnology sector, particularly for advanced therapies like those based on mRNA technology.